Inventor · disambiguated record
Andrew T. Metcalf
Also filed as: METCALF ANDREW · METCALF ANDREW T · METCALF ANDREW TERRANCE
29 granted patents·6 pending applications·144 citations·filing 2011–2024
96Inventor score
Top patents by PatentIndex Score
35 records- 0198US10112942B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 30, 2018·29 cites·30 claims
- 0297US10953005B1Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2020·Granted Mar 23, 2021·4 cites·16 claims
- 0397US10137124B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Nov 27, 2018·12 cites·29 claims
- 0496US10208024B22-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2016·Granted Feb 19, 2019·32 cites·27 claims
- 0596US10172851B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·8 cites·29 claims
- 0694US11414404B2Compounds for the treatment of BRAF-associated diseases and disordersARRAY BIOPHARMA INC·Filed 2020·Granted Aug 16, 2022·5 cites·14 claims
- 0794US10555944B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Feb 11, 2020·10 cites·12 claims
- 0892US10584124B2Crystalline formsARRAY BIOPHARMA INC·Filed 2018·Granted Mar 10, 2020·12 cites·9 claims
- 0991US10172845B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·4 cites·29 claims
- 1089US12209086B2FGFR3 inhibitor compoundsLILLY CO ELI·Filed 2023·Granted Jan 28, 2025·1 cites·44 claims
- 1189US10144734B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Dec 4, 2018·6 cites·30 claims
- 1288US10441581B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Oct 15, 2019·2 cites·29 claims
- 1387US11998545B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2023·Granted Jun 4, 2024·0 cites·14 claims
- 1487US11878976B2FGFR3 inhibitor compoundsLILLY CO ELI·Filed 2022·Granted Jan 23, 2024·1 cites·37 claims
- 1585US9763942B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Sep 19, 2017·5 cites·18 claims
- 1684US10745419B2Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileLOXO ONCOLOGY INC·Filed 2018·Granted Aug 18, 2020·2 cites·19 claims
- 1782US10881652B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Jan 5, 2021·2 cites·14 claims
- 1882US10154995B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Dec 18, 2018·3 cites·18 claims
- 1981US11098064B2Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrileLOXO ONCOLOGY INC·Filed 2020·Granted Aug 24, 2021·1 cites·9 claims
- 2081US9670208B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Jun 6, 2017·4 cites·19 claims
- 2180US2023090520A1Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2278US2025122196A1Fgfr3 inhibitor compoundsLILLY CO ELI·Filed 2024·Application pending·0 cites
- 2376US2021186959A1Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2475US11247990B1Bicyclic fused pyridine compounds as inhibitors of TAM kinasesARRAY BIOPHARMA INC·Filed 2018·Granted Feb 15, 2022·1 cites·20 claims
- 2572US11648243B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2020·Granted May 16, 2023·0 cites·20 claims
- 2671US11634409B2Compounds for the treatment of BRAF-associated diseases and disordersARRAY BIOPHARMA INC·Filed 2022·Granted Apr 25, 2023·0 cites·42 claims
- 2769US11807651B2Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileLOXO ONCOLOGY INC·Filed 2021·Granted Nov 7, 2023·0 cites·11 claims
- 2865US10766881B22-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2019·Granted Sep 8, 2020·0 cites·21 claims
- 2964US2025197413A1Rxfp1 receptor agonistsLILLY CO ELI·Filed 2024·Application pending·0 cites
- 3050US11603374B2Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Mar 14, 2023·0 cites·12 claims
- 3150US2025263409A1Fgfr2 inhibitor compoundsLILLY CO ELI·Filed 2023·Application pending·0 cites
- 3249US11472802B2Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Oct 18, 2022·0 cites·11 claims
- 3347US11964988B2Fused heterocyclic compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Apr 23, 2024·0 cites·18 claims
- 3447US11524963B2Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Dec 13, 2022·0 cites·18 claims
- 3535US2012157448A1Compounds for treating neurodegenerative diseasesCOOK ADAM·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →